Skip to main content

Advertisement

Table 1 Viability and phenotype of BM-MSCs ejected via 26 G bore size needle for multiple times

From: Impact of passing mesenchymal stem cells through smaller bore size needles for subsequent use in patients for clinical or cosmetic indications

  Control 2nd Jab 4th Jab 6th Jab 8th Jab 10th Jab
Viability 98.25% ± 1.45 96.98% ± 2.11 97.38% ± 2.23 95.89% ± 1.89 96.18% ± 2.19 97.35% ± 1.95
CD44 98.68% ± 1.42 98.89% ± 1.18 98.13% ± 1.56 98.54% ± 1.39 98.72% ± 1.28 98.31% ± 1.49
CD73 98.97% ± 1.16 98.63% ± 1.36 98.48% ± 1.41 98.77% ± 1.29 98.22% ± 1.67 98.41% ± 1.37
CD166 96.48% ± 2.24 97.12% ± 2.16 96.29% ± 2.31 97.71% ± 2.24 97.11% ± 2.18 96.89% ± 2.29
CD34 0.02% 0.23% 0.76% 0.94% 0.68% 0.85%
CD45 0.06% 0.66% 0.47% 0.57% 0.81% 0.90%
HLA-DR 0.05% 0.11% 0.76% 0.84% 0.93% 0.18%